<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657005</url>
  </required_header>
  <id_info>
    <org_study_id>TK216-01</org_study_id>
    <nct_id>NCT02657005</nct_id>
  </id_info>
  <brief_title>TK216 in Patients With Relapsed or Refractory Ewing Sarcoma</brief_title>
  <official_title>A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncternal Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncternal Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ewing sarcoma is characterized by genomic rearrangements resulting in over-expression of ets
      family transcription factors driving tumor progression. TK216 is designed to inhibit this
      effect by inhibiting downstream effects of the EWS-FLI1 transcription factor. This study is a
      first in human study of TK216 in subjects with Ewing sarcoma. The study is designed to
      establish initial safety and efficacy data to assess the potential of TK216 for further
      development.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLTs)</measure>
    <time_frame>18 months</time_frame>
    <description>Listing of dose-limiting toxicities by daily dose in mg/m^2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>18 months</time_frame>
    <description>Maximum daily dose in mg/m^2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biologically effective and recommended Phase 2 dose (RP2D)</measure>
    <time_frame>18 months</time_frame>
    <description>Daily dose in mg/m^2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity as measured by Overall Response Rate (ORR)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity as measured by Duration of Response (DOR)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Disease Control</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assay methods to detect EWS-FLI1 (or EWS-ERG and EWS-ets)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Curve [AUC]</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Halflife [T1/2]</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: serum miRNA profile</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: tumor tissue RNA assays</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: tumor tissue protein assays</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Sarcoma, Ewing</condition>
  <arm_group>
    <arm_group_label>TK216 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation and expansion cohorts to determine dose-limiting toxicities, maximally tolerated dose, preliminary efficacy, and recommended phase 2 dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TK216</intervention_name>
    <description>Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein</description>
    <arm_group_label>TK216 treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of Ewing sarcoma (including ESFT)
             in subjects with relapsed or refractory disease who have failed standard therapy

        Exclusion Criteria:

          -  Symptomatic brain metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Breitmeyer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oncternal Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tilman Oltersdorf, MD</last_name>
    <phone>760 274 5789</phone>
    <email>tilman@oltersdorf.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deborah Jezior</last_name>
    <email>DJezior@oncternal.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Bernardo</last_name>
      <phone>310-794-8086</phone>
      <email>mjbernardo@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Noah Federman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Widener</last_name>
      <email>etp@childrenscolorado.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyn Winchester</last_name>
      <phone>646-888-5711</phone>
      <email>winchesm@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Bonura</last_name>
      <email>DirenzoJ@mskcc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Paul A Meyers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph A Ludwig, MD</last_name>
      <phone>713-792-3626</phone>
    </contact>
    <investigator>
      <last_name>Joseph A Ludwig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

